Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Payables: 2010-2025

Historic Payables for Madrigal Pharmaceuticals (MDGL) over the last 12 years, with Sep 2025 value amounting to $44.9 million.

  • Madrigal Pharmaceuticals' Payables fell 2.23% to $44.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $168.6 million, marking a year-over-year increase of 61.27%. This contributed to the annual value of $43.6 million for FY2024, which is 55.48% up from last year.
  • Madrigal Pharmaceuticals' Payables amounted to $44.9 million in Q3 2025, which was up 18.34% from $38.0 million recorded in Q2 2025.
  • In the past 5 years, Madrigal Pharmaceuticals' Payables ranged from a high of $46.0 million in Q3 2024 and a low of $1.1 million during Q2 2021.
  • Moreover, its 3-year median value for Payables was $28.0 million (2023), whereas its average is $29.0 million.
  • Data for Madrigal Pharmaceuticals' Payables shows a peak YoY increase of 2,002.26% (in 2021) and a maximum YoY decrease of 78.68% (in 2021) over the last 5 years.
  • Madrigal Pharmaceuticals' Payables (Quarterly) stood at $21.4 million in 2021, then climbed by 11.46% to $23.8 million in 2022, then grew by 17.67% to $28.0 million in 2023, then soared by 55.48% to $43.6 million in 2024, then dropped by 2.23% to $44.9 million in 2025.
  • Its Payables was $44.9 million in Q3 2025, compared to $38.0 million in Q2 2025 and $42.1 million in Q1 2025.